These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 21496064

  • 21. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
    Skinner MH, Kuan HY, Pan A, Sathirakul K, Knadler MP, Gonzales CR, Yeo KP, Reddy S, Lim M, Ayan-Oshodi M, Wise SD.
    Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
    [Abstract] [Full Text] [Related]

  • 22. Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol.
    Parker RB, Soberman JE.
    Pharmacotherapy; 2011 Jul; 31(7):630-41. PubMed ID: 21923449
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects.
    Chen L, Boinpally R, Gad N, Greenberg WM, Wangsa J, Periclou A, Ghahramani P.
    Clin Drug Investig; 2015 Oct; 35(10):601-12. PubMed ID: 26315684
    [Abstract] [Full Text] [Related]

  • 24. The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers.
    Schneider F, Stamler D, Bradbury MJ, Loupe PS, Gordon MF, Rabinovich-Guilatt L.
    Eur J Clin Pharmacol; 2022 Jan; 78(1):11-18. PubMed ID: 34491372
    [Abstract] [Full Text] [Related]

  • 25. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
    Hoch M, Hoever P, Alessi F, Theodor R, Dingemanse J.
    Eur J Clin Pharmacol; 2013 Mar; 69(3):523-32. PubMed ID: 22990330
    [Abstract] [Full Text] [Related]

  • 26. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.
    Brynne N, Forslund C, Hallén B, Gustafsson LL, Bertilsson L.
    Br J Clin Pharmacol; 1999 Oct; 48(4):564-72. PubMed ID: 10583027
    [Abstract] [Full Text] [Related]

  • 27. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.
    Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D.
    J Clin Pharmacol; 2011 Dec; 51(12):1721-7. PubMed ID: 21148045
    [Abstract] [Full Text] [Related]

  • 28. Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene.
    Ouellet D, Bramson C, Roman D, Remmers AE, Randinitis E, Milton A, Gardner M.
    Br J Clin Pharmacol; 2007 Jan; 63(1):59-66. PubMed ID: 16822276
    [Abstract] [Full Text] [Related]

  • 29. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
    Lin J, Goosen TC, Tse S, Yamagami H, Malhotra B.
    J Clin Pharmacol; 2019 Nov; 59(11):1505-1518. PubMed ID: 31090092
    [Abstract] [Full Text] [Related]

  • 30. Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers.
    Shaik MN, LaBadie RR, Rudin D, Levin WJ.
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):411-8. PubMed ID: 24944041
    [Abstract] [Full Text] [Related]

  • 31. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
    Lim KS, Jang IJ, Kim BH, Kim J, Jeon JY, Tae YM, Yi S, Eum S, Cho JY, Shin SG, Yu KS.
    Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
    [Abstract] [Full Text] [Related]

  • 32. Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
    Kuhn UD, Kirsch M, Merkel U, Eberhardt AM, Wenda B, Maurer I, Härtter S, Hiemke C, Volz HP, Balogh A.
    Int J Clin Pharmacol Ther; 2007 Jan; 45(1):36-46. PubMed ID: 17256449
    [Abstract] [Full Text] [Related]

  • 33. Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions.
    Boetsch C, Parrott N, Fowler S, Poirier A, Hainzl D, Banken L, Martin-Facklam M, Hofmann C.
    Clin Pharmacokinet; 2016 Feb; 55(2):237-47. PubMed ID: 26341813
    [Abstract] [Full Text] [Related]

  • 34. Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men.
    Martin DE, Zussman BD, Everitt DE, Benincosa LJ, Etheredge RC, Jorkasky DK.
    J Clin Psychopharmacol; 1997 Dec; 17(6):451-9. PubMed ID: 9408807
    [Abstract] [Full Text] [Related]

  • 35. Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects.
    Yasui-Furukori N, Saito M, Inoue Y, Niioka T, Sato Y, Tsuchimine S, Kaneko S.
    Eur J Clin Pharmacol; 2007 Jan; 63(1):51-6. PubMed ID: 17124578
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK-453,061), in healthy adult subjects.
    Langdon G, Davis J, Layton G, Chong CL, Weissgerber G, Vourvahis M.
    Br J Clin Pharmacol; 2012 May; 73(5):768-75. PubMed ID: 22040521
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.